AbCellera Biologics (ABCL) Operating Income: 2019-2024
Historic Operating Income for AbCellera Biologics (ABCL) over the last 6 years, with Dec 2024 value amounting to -$314.8 million.
- AbCellera Biologics' Operating Income fell 74.85% to -$66.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$237.2 million, marking a year-over-year decrease of 209.56%. This contributed to the annual value of -$314.8 million for FY2024, which is 32.70% down from last year.
- According to the latest figures from FY2024, AbCellera Biologics' Operating Income is -$314.8 million, which was down 32.70% from -$237.2 million recorded in FY2023.
- AbCellera Biologics' Operating Income's 5-year high stood at $216.5 million during FY2022, with a 5-year trough of -$314.8 million in FY2024.
- Moreover, its 3-year median value for Operating Income was -$237.2 million (2023), whereas its average is -$111.8 million.
- In the last 5 years, AbCellera Biologics' Operating Income skyrocketed by 3,889.92% in 2020 and then slumped by 209.56% in 2023.
- Yearly analysis of 5 years shows AbCellera Biologics' Operating Income stood at $156.0 million in 2020, then skyrocketed by 31.01% to $204.4 million in 2021, then climbed by 5.92% to $216.5 million in 2022, then plummeted by 209.56% to -$237.2 million in 2023, then slumped by 32.70% to -$314.8 million in 2024.